• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

JPM 2022: Bluebird bio hopes for clear skies ahead as it gears up for trio of gene therapy...

cafead

Administrator
Staff member
  • cafead   Jan 13, 2022 at 10:52: PM
via Bluebird is readying the commercial nest ahead of a May decision on its beta thalassemia gene therapy beti-cel, also known as Zynteglo. Those preparations will be "crucial" to unlocking the blockbuster potential of lovo-cel in sickle cell disease (SCD) next year, should that drug pass muster at the FDA, bluebird CEO Andrew Obenshain said Wednesday at the 2022 J.P. Morgan Healthcare Conference.

article source
 

<